Sweden's Egetis revenue up 40% but misses estimates

Egetis Therapeutics AB (publ)

26/02/2026 06:21

Overview

Sweden pharma firm's 2025 revenue missed analyst expectations

Company completed U.S. rolling NDA submission for Emcitate®

Company announced positive results from ReTRIACt study

Outlook

Company aims for Emcitate approval in second half of 2026

Egetis plans U.S. Emcitate launch in fourth quarter of 2026

Company focuses on optimizing Emcitate pricing and reimbursement in Europe

Result Drivers

EMCITATE REVENUE GROWTH - Emcitate revenue increased by 40% in 2025, attributed to its launch in the EU, especially in Germany

POSITIVE STUDY RESULTS - Positive results from the ReTRIACt study supported the NDA submission for Emcitate

EXPANDED DISTRIBUTION - Egetis expanded Emcitate's market reach through agreements in the Gulf Region and Europe

Company press release: ID:nMFN8YCzb5

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
SEK 62.4 mln
SEK 67.15 mln (6 Analysts)
FY Adjusted EPS
-SEK 0.90
FY Net Income
-SEK 342.5 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Egetis Therapeutics AB (publ) is SEK14.00, about 200.4% above its February 25 closing price of SEK4.66

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)